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Essential fatty acids and inflammation
Essential fatty acids are 'essential'" not only because of their
physiological importance but because they must be derived
in either direct or partially elaborated form from the diet.
Thus these acids may be classified as vitamins (indeed they
were once called vitamin F).
Two groups of fatty acids are essential to the body: the W6
(n6) series, derived from linoleic acid (18:2 n-6) and the W3
(n6) series, derived from a-linolenic acid (18:3 n-3). In these
notations 18 is the number of carbon atoms in the molecule,
the second number is the number of double carbon-carbon
bonds (degree of unsaturation), and the number after the n
is the position of the first double bond starting from the
methyl (w) end of the fatty acid chain. The figure shows the
sequences of the two fatty acids. Fatty acids provide energy,
are an integral part of cell membranes, and are precursors for
prostaglandins, thromboxanes, and leukotrienes, collectively
termed eicosanoids. Abundant experimental evidence
supports the view that eicosanoids participate in develop-
ment and regulation of immunological and inflammatory
responses. Because most rheumatic diseases are characterised
by inflammation, disordered immune regulation, and tissue
injury there is much interest among rheumatologists in the
role of eicosanoids in regulation of host defences. As the
detrimental effects of therapy for the rheumatic diseases
may be more difficult to manage than the diseases themselves
there is a need for new, safe approaches to the treatment of
these patients. Alteration of the eicosanoid profile by
administration offatty acid precursors other than arachidonic
acid is one approach under investigation.
As eicosanoids derive from essential fatty acids, dietary
manipulation or direct administration of precursor fatty
acids has been used to alter the eicosanoid profile.
Although changes in eicosanoid production owing to
alteration of fatty acid intake form the basis of the current
hypothesis for the anti-inflammatory effects of this type of
treatment, it is likely that the precursor fatty acids
themselves may alter immune responses. Animal and
human studies have shown that changes in essential fatty
acid intake alter the fatty acid composition of cell mem-
branes.2 For example, in essential fatty acid deficiency,
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deprivation of linoleic acid leads to deficiency of arachidonic
acid and impairment of prostaglandin synthesis. Essential
fatty acid deficiency causes many pathological changes, but
it also reduces the severity of inflammation in experimental
animal models. Fasting also has a salutary effect on
symptoms of patients with rheumatoid arthritis.3 As neither
induction of essential fatty acid deficiency nor fasting are
likely to be popular treatments it might be more prudent to
modify or supplement, rather than delete, lipid intake.
The extraordinary rapidity with which platelets adhere to
damaged tissue, aggregate, and release potent biologically
active materials suggests that the platelet is well suited to be
a cellular trigger for the inflammatory process.4 Thus efforts
directed at suppression of thromboxane synthesis, enhance-
ment of prostacyclin (prostaglandin I2) production, and
inhibition of platelet aggregation may result in limitation of
inflammatory responses. Fish oil lipids, rich in eicosapen-
taenoic acid (20:5 n3), inhibit formation of cyclo-oxygenase
products (thromboxane A2, prostaglandin E2) derived from
arachidonate. Newly formed throboxane A3 has much less
ability than thromboxane A2 to constrict vessels and aggre-
gate platelets. In addition, production of prostaglandin I2 by
endothelial cells is not reduced appreciably by increased
eicosapentaenoic acid content, and the physiological activity
of newly synthesised prostaglandin I3 is added to that of
prostaglandin I2.5 Diets enriched in fish oil also reduce the
amount of leukotriene B4 generated via the 5-lipoxygenase
pathway in stimulated neutrophils and monocytes, suppress
the chemotactic response of neutrophils to leukotriene B4,
and reduce generation of platelet activating factor, inter-
leukin 1, and tumour necrosis factor by stimulated mono-
cytes.6 ' Fish oil supplements have therefore been used in
attempts to suppress inflammation in experimental models
and in patients with rheumatoid arthritis.>'0 Therapeutic
benefits have been modest but encouraging. Evidence that
fish oil administration enhances collagen induced arthritis in
rats and exacerbates vasculitis in autoimmune mice"
dictates caution in the premature uncontrolled use of fish oil
treatments in inflammatory diseases.
Evidence obtained from experiments in vitro and in vivo
in small animals and humans suggests that other novel fatty
acids may be safe and effective anti-inflammatory and
immunomodulatory agents. For example, certain botanical
lipids, notably those extracted from seeds of the evening
primrose and borage plants, contain relatively large
amounts of y-linolenic acid (18:3 n-6). This acid is
converted rapidly to dihomo-y-linolenic acid (20:3 n-6) the
fatty acid precursor of the monoenoic prostaglandins-for
example, prostaglandin El. In humans the 65 desaturase
which converts dihomo-y-linolenic acid to arachidonic acid
is sluggish. Thus concentrations of arachidonate do not
increase appreciably. Dihomo-y-linolenic acid competes
with arachidonate for oxidative enzymes, thereby reducing
production of cyclo-oxygenase products derived from
arachidonate. In addition, dihomo-y-linolenic acid cannot
be converted to inflammatory leukotrienes by 5-
lipoxygenase. Instead, it is converted to 15-hydroxy-
dihomo-y-linolenic acid, which has the added ability of
inhibiting 5-lipoxygenase activity.'2
y-Linolenic acid enrichment of diet suppresses acute and
chronic inflammation as well as joint tissue injury in several
experimental animal models.13 In animals treated with
evening primrose or borage seed oils, cells from inflamma-
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tory exudate are enriched in y-linolenic acid and its
elongated product dihomo-y-linolenic acid. Exudate prosta-
glandin E2 and leukotriene B4 concentrations are reduced
and leucocyte effector functions (chemotaxis, lysosomal
enzyme release) are suppressed. Enrichment with dihomo-
y-linolenic acid of synovial cells in culture leads to a marked
reduction of prostaglandin E2 synthesis, a substantial
increase in prostaglandin El production, and reduction in
interleukin 1 induced synovial cell proliferation. Addition to
cultures of arachidonic acid (which increases prostaglandin
E2 substantially) or eicosapentaenoic acid does not modify
synovial cell proliferation. The antiproliferative effect of
dihomo-y-linolenic acid is prevented by indomethacin.'4
Thus both marine and botanical lipids have anti-inflamma-
tory actions owing to their ability to reduce synthesis of
oxygenation products of arachidonic acid which are potent
mediators of inflammation.
In addition to their role as eicosanoid precursors, fatty
acids are of major importance in maintaining cell membrane
structure and are key determinants of the behaviour of
membrane bound enzymes and receptors.'5 The fatty acid
precursors can exert these functions directly and therefore
may themselves be important regulators of immune
responses. Dihomo-y-linolenic acid suppresses interleukin 2
production by human peripheral blood mononuclear cells in
vitro, suppresses proliferation of interleukin 2 dependent
human T lymphocytes, and reduces expression of activation
markers on T lymphocytes directly, in a manner which is
independent of conversion to prostaglandin. 6 The observa-
tions indicate that fatty acids can modulate immune
responses by acting directly on T cells and suggest that
alteration of cellular fatty acids may be a worthwhile
approach to control of inflammation.
Inflammation is central to the cutaneous manifestations of
psoriasis and atopic eczema. In both conditions leukotriene
B4 and 12-hydroxyeicosatetraenoic acid concentrations are
increased in affected skin. Controlled trials, in which y-
linolenic acid (in primrose seed oil) was used to treat atopic
eczema, showed sufficient clinical benefit to warrant
approval of such treatment by the National Health Service. 7
Administration of 1 1 g/day y-linolenic acid to volunteers
and patients with rheumatoid arthritis for 12 weeks (in an
uncontrolled manner) resulted in enrichment of leucocytes
with dihomo-y-linolenic acid, significant reductions in
monocyte prostaglandin E2 and leukotrienes B4 and C4, and
reduced synovitis in six of seven patients.'8 Other studies
have shown that y-linolenic acid administration leads to
increased prostaglandin El production by monocytes.'9 A
preliminary report2l indicating that 1 2 g y-linolenic acid/
day given to normal volunteers for six weeks reduced
interleukin 1 production by stimulated peripheral blood
monocytes may also be relevant to its potential therapeutic
effects. y-Linolenic acid (540 mg/day in primrose seed oil)
has been shown, in a 12 month long placebo controlled,
double blind study to reduce pain and the need for non-
steroidal anti-inflammatory drugs in patients with rheuma-
toid arthritis.2' Lower doses of the acid (480 mg/day), used
for shorter periods of time (12 weeks), were not useful
treatment for patients with rheumatoid arthritis.22 23 It may
be of interest that in one of the negative studies22 the y-
linolenic acid supplement could be substituted for the non-
steroidal anti-inflammatory drugs. Clearly, long term,
multicentre, placebo controlled studies of a large number of
patients are needed to determine whether any form of
treatment is useful for patients with rheumatoid arthritis.
Few adverse effects of marine or botanical lipid adminis-
tration have been noted; stool softening and abdominal
bloating have been reported. Nonetheless, potential adverse
effects cannot be dismissed. Experience teaches that the
longer a given treatment is used the greater the incidence of
adverse effects. Administration of long chain poly-
unsaturated fatty acids increases the likelihood of lipid
peroxidation with its associated toxic effects on cells. It is
not known whether an increased requirement for an
antioxidant (such as vitamins E and C) accompanies
increased intake of long chain unsaturated fatty acids.
Because these novel fatty acids can reduce inflammation and
affect immunocytes the question arises as to whether they
can compromise the immune system. Susceptibility to
infection has not been seen as yet but must be considered.
The potential ability of particular fatty acids to regulate
cell activation, immune responses, and inflammation is
exciting to consider at the clinical, cellular, and molecular
levels. A better understanding of how fatty acids modulate
function of cells involved in host defence might lead to
development of new, benign treatment for diseases charac-
terised by acute and chronic inflammation.
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